Pioglitazone and risk of bladder cancer: Clarification of the design of the French study

Diabetologia

Volumn 56, Issue 1, 2013, Pages 227-

  Perez, A T ^a  

^a Takeda Global Research   (United States)

Author keywords

Bladder cancer; Diabetes; Pioglitazone; Smoking; TZDs

Indexed keywords

PIOGLITAZONE;

BLADDER CANCER; CANCER RISK; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE DURATION; FRANCE; HUMAN; INCIDENCE; LETTER; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84871607538     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2767-y     Document Type: Letter

References (4)

1. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 55:1953-1962
2. Lewis JD, Ferrara A, Peng T et al. (2011) Risk of bladder cancer among diabetic patients treated with Pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916-922
3. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Cohort study of pioglitazone and bladder cancer in patients with type II diabetes. Updated 17 August 2012. Available at: http://www.encepp.eu/encepp/viewResource.htm?id=2718, accessed 11 October 2012
4. Caisse Nationale de l'Assurance Maladie (2011) Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les donnée du SNIIRAM et du PMSI. Available at http://ansm.sante.fr/content/download/34024/445581/version/1/ file/RapportEtudeCNAMTS-Pioglitazone-juin-20113.pdf, accessed 9 June, 2011 (article in French)